ArticleCureus2024
An Analysis of Cost Variation Among Drugs Available in the Indian Market for the Treatment of Chronic Bone-Related Ailments.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreating widely prevalent bone illnesses such as back and neck pain, osteoarthritis, rheumatoid arthritis, gout, and osteoporosis with pharmacological medication can be excessively costly for both the individual and their family. This study aimed to conduct a cost minimization analysis by comparing the prices of Jan Aushadhi (JA) medications with the most expensive and least expensive branded alternatives available in India.
methodsThe prices of the most costly, least costly branded, and JA medicines were acquired from the relevant websites. The cost difference, cost ratio, and percentage of cost variation were determined based on the guidelines outlined in the cost minimization analysis research.
resultsA total of 67 drugs/combinations used to treat various chronic bone ailments were analyzed. With regard to analgesic/anti-inflammatory drugs, the most expensive brand of diclofenac sodium + serratiopeptidase (50mg + 10mg) tablet was 32.5 times more expensive than the cheapest and 10.5 times more costly than the JA brand. Also, the paracetamol 325mg + tramadol 37.5mg combination of the branded tablets was more expensive than JA. Branded cyclosporine was 2.3 times more expensive than JA among immunosuppressants in the disease-modifying antirheumatic drugs (DMARD) group. The most expensive immunomodulator, leflunomide, costs four times more than JA. Hydrocortisone injection, an adjuvant, costs 10.8 times more than the cheapest and 2.1 times more than JA. IL-1 inhibitor + nutraceutical combination costs 4.8 times more than the costliest JA brand. Zoledronic acid was 16.1 and 6.8 times more expensive than the cheapest branded and JA drugs. Xanthine oxidase inhibitor febuxostat, used to treat gout, costs 5.2 and 3.3 times more than JA and the cheapest brands.
conclusionThis cost minimization study, the first to the best of our knowledge in the field of chronic musculoskeletal ailments, indicates the usefulness of JA drugs in reducing the patient's financial costs for most drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.